1. Bray, F, Ferlay, J, Soerjomataram, I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
Google Scholar | Crossref | Medline2. Arnold, M, Karim-Kos, HE, Coebergh, JW, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer 2015; 51: 1164–1187.
Google Scholar | Crossref | Medline | ISI3. Hakama, M, Moss, SM, Stenman, UH, et al. Design-corrected variation by centre in mortality reduction in the ERSPC randomised prostate cancer screening trial. J Med Screen 2017; 24: 98–103.
Google Scholar | SAGE Journals | ISI4. Catalona, WJ, Smith, DS, Ratliff, TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen—based screening. JAMA J Am Med Assoc 1993; 270: 948–954.
Google Scholar | Crossref | Medline | ISI5. Babaian, RJ, Mettlin, C, Kane, R, et al. The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Cancer 1992; 69: 1195–1200.
Google Scholar | Crossref | Medline6. Brawer, MK, Chetner, MP, Beatie, J, et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147: 841–845.
Google Scholar | Crossref | Medline | ISI7. Mettlin, C, Murphy, GP, Lee, F, et al. Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. Cancer 1993; 72: 1701–1708.
Google Scholar | Crossref | Medline | ISI8. Pinsky, PF, Prorok, PC, Yu, K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 2017; 123: 592–599.
Google Scholar | Crossref | Medline9. Lilja, H, Ulmert, D, Vickers, AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008; 8: 268–278.
Google Scholar | Crossref | Medline | ISI10. Polascik, TJ, Oesterling, JE, Partin, AW. Prostate specific antigen: a decade of discovery - What we have learned and where we are going. J Urol 1999; 162: 293–306.
Google Scholar | Crossref | Medline | ISI11. Public Health England . PSA prostate cancer test guideline. PHE/DH/DWP guideline, https://www.guidelines.co.uk/cancer/phe-psa-prostate-cancer-test-guideline-/252826.article (accessed 7 June 2021).
Google Scholar12. National Institute for Health Care and Excellence . Prostate cancer: diagnosis and management. Guidance. NICE, https://www.nice.org.uk/guidance/ng131 (accessed 7 June 2021).
Google Scholar13. Gretzer, MB, Partin, AW. PSA markers in prostate cancer detection. Urol Clin North Am 2003; 30: 677–686.
Google Scholar | Crossref | Medline14. Partin, AW, Brawer, MK, Subong, ENP, et al. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis 1998; 1: 197–203.
Google Scholar | Crossref | Medline | ISI15. Becerra, MF, Bhat, A, Mouzannar, A, et al. Serum and urinary biomarkers for detection and active surveillance of prostate cancer. Curr Opin Urol 2019; 29: 593–597.
Google Scholar | Crossref | Medline16. Filella, X, Albaladejo, MD, Allué, JA, et al. Prostate cancer screening: guidelines review and laboratory issues. Clin Chem Lab Med 2019; 57: 1474–1487.
Google Scholar | Crossref | Medline17. Kretschmer, A, Tilki, D. Biomarkers in prostate cancer - Current clinical utility and future perspectives. Crit Rev Oncol Hematol 2017; 120: 180–193.
Google Scholar | Crossref | Medline18. Vickers, AJ, Cronin, AM, Roobol, MJ, et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res 2010; 16: 3232–3239.
Google Scholar | Crossref | Medline | ISI19. Vickers, AJ, Cronin, AM, Aus, G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of prostate cancer Screening in Göteborg, Sweden. BMC Med 2008; 6: 19. DOI: 10.1186/1741-7015-6-19.
Google Scholar | Crossref | Medline | ISI20. McDonald, ML, Parsons, JK. 4-Kallikrein Test and Kallikrein markers in prostate cancer screening. Urol Clin North Am 2016; 43: 39–46.
Google Scholar | Crossref | Medline21. Vickers, A, Cronin, A, Roobol, M, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-Kallikrein panel: an independent replication. J Clin Oncol 2010; 28: 2493–2498.
Google Scholar | Crossref | Medline | ISI22. Stattin, P, Vickers, AJ, Sjoberg, DD, et al. Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of Kallikrein Markers: a nested case-control study. Eur Urol 2015; 68: 207–13.
Google Scholar | Crossref | Medline23. Parekh, DJ, Punnen, S, Sjoberg, DD, et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol 2015; 68: 464–470.
Google Scholar | Crossref | Medline24. European Association of Urology . EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. https://uroweb.org/wp-content/uploads/EAU-ESUR-ESTRO-SIOG-Guidelines-on-Prostate-Cancer-large-text-V2.pdf (2018, accessed 10 October 2019).
Google Scholar25. National Comprehensive Cancer Network . NCCN Guidelines Version 2.2019 Prostate Cancer Early Detection, https://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf (2019, accessed 8 October 2019).
Google Scholar26. ARUP Laboratories . 4Kscore (Prostate-Specific Kallikrein). https://www.aruplab.com/4kscore (accessed 10 February 2020).
Google Scholar27. Mikolajczyk, SD, Marks, LS, Partin, AW, et al. Free prostate-specific antigen in serum is becoming more complex. Urology 2002; 59: 797–802.
Google Scholar | Crossref | Medline28. Lazzeri, M, Haese, A, Abrate, A, et al. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS . BJU Int 2013; 112: 313–321.
Google Scholar | Crossref | Medline | ISI29. White, J, Shenoy, BV, Tutrone, RF, et al. Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. Prostate Cancer Prostatic Dis 2018; 21: 78–84.
Google Scholar | Crossref | Medline30. Jansen, FH, van Schaik, RHN, Kurstjens, J, et al. Prostate-Specific Antigen (PSA) Isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010; 57: 921–927.
Google Scholar | Crossref | Medline | ISI31. Le, B V., Griffin, CR, Loeb, S, et al. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from Benign disease in a prospective prostate cancer screening study. J Urol 2010; 183: 1355–1359.
Google Scholar | Crossref | Medline | ISI32. Sokoll, LJ, Sanda, MG, Feng, Z, et al. A prospective, multicenter, national cancer institute early detection research network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010; 19: 1193–1200.
Google Scholar | Crossref | Medline | ISI33. Stephan, C, Vincendeau, S, Houlgatte, A, et al. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem 2013; 59: 306–314.
Google Scholar | Crossref | Medline34. Filella, X, Giménez, N. Evaluation of [ - 2] proPSA and prostate health index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013; 51: 729–739.
Google Scholar | Medline | ISI35. Mikolajczyk, SD, Catalona, WJ, Evans, CL, et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 2004; 50: 1017–1025.
Google Scholar | Crossref | Medline | ISI36. Ito, K, Miyakubo, M, Sekine, Y, et al. Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range. World J Urol 2013; 31: 305–311.
Google Scholar | Crossref | Medline37. Catalona, WJ, Partin, AW, Sanda, MG, et al. A Multi-Center study of [-2]pro-prostate specific antigen (PSA) in combination with PSA and free PSA for prostate cancer detection in the 2.0 to 10.0 ng/ml PSA range. J Urol 2011; 185: 1650–5.
Google Scholar | Crossref | Medline | ISI38. Jansen, FH, van Schaik, RHN, Kurstjens, J, et al. Prostate-Specific Antigen (PSA) Isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010; 57: 921–927.
Google Scholar | Crossref | Medline | ISI39. Guazzoni, G, Lazzeri, M, Nava, L, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012; 61: 455–66.
Google Scholar | Crossref | Medline | ISI40. Stephan, C, Kahrs, A-M, Cammann, H, et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009; 69: 198–207.
Google Scholar | Crossref | Medline41. Tosoian, JJ, Druskin, SC, Andreas, D, et al. Prostate Health Index density improves detection of clinically significant prostate cancer. BJU Int 2017; 120: 793–798.
Google Scholar | Crossref | Medline42. Druskin, SC, Tosoian, JJ, Young, A, et al. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer. BJU Int 2018; 121: 619–626.
Google Scholar | Crossref | Medline43. Carter, HB, Albertsen, PC, Barry, MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol 2013; 190: 419–426.
Google Scholar | Crossref | Medline | ISI44. Leyten, GHJM, Hessels, D, Smit, FP, et al. Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res 2015; 21: 3061–3070.
Google Scholar | Crossref | Medline45. Van Neste, L, Hendriks, RJ, Dijkstra, S, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker–based risk score. Eur Urol 2016; 70: 740–748.
Google Scholar | Crossref | Medline46. Govers, TM, Hessels, D, Vlaeminck-Guillem, V, et al. Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. Prostate Cancer Prostatic Dis 2019; 22: 101–109.
Google Scholar | Crossref | Medline47. Haese, A, Trooskens, G, Steyaert, S, et al. M